HOME >> BIOLOGY >> NEWS
New research on safety of intracoronary delivery of adenovector reported in cover story of Molecular Therapy

SAN DIEGO, California December 3, 2001 Collateral Therapeutics, Inc. (Nasdaq: CLTX) announced that preclinical in vitro and in vivo results reported in the December 2001 issue of Molecular Therapy showed that male reproductive cells (germ cells) were unaffected following intracoronary delivery of Collaterals adenovector (adenovirus serotype 5 Ad5). These findings confirm other research studies in which potential risks associated with inadvertent germ line transmission following adenoviral administration have been shown to be highly unlikely.

In the study, led by Robert E. Braun, Ph.D. Associate Professor of Genetics at the University of Washington, gene expression after adenovirus delivery was analyzed from a series of both in vitro and in vivo studies. The in vitro studies demonstrated that germ cells grown in cell culture were refractory to infection by Collaterals adenovector. To assess the risk of germ line transmission in vivo, researchers used a mouse model to deliver human recombinant Ad5 carrying a germ cell-specific promoter fused to a reporter gene directly into the left ventricular cavity of the heart. They observed that the reporter gene protein was not expressed in developing spermatids or mature sperm, with analyses performed at multiple time points after administration to evaluate all major stages of germ cell development. Importantly, the in vivo studies did not detect infection of the reproductive stem cells. The positive results from these studies are consistent with other recent studies using different models and routes of delivery. However, this is the first study that directly assessed the ability of an adenovirus to result in gene expression in extremely large numbers (i.e., millions) of germ line cells, and the first to assay infection of the reproductive stem cell population.

This study provides significant new information further supporting the safety of the use of the adenovirus as a vehicle to deliver therapeut
'"/>

Contact: Lora Pike
lpike@collateralthx.com
858-794-3410
Collateral Therapeutics
1-Dec-2001


Page: 1 2 3

Related biology news :

1. Leader in cancer treatment and prevention research honored
2. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative
3. Scientists to prototype cyberinfrastructure for research and education access to ocean observatories
4. Belgian researchers explore revolutionary approach to angiogenesis
5. Award winning researchers reveal potential new role for Glivec
6. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
7. 16 APS exercise research highlights, from reduced flu mortality to proteomics & obesity
8. Gene chips research in cotton could lead to superior variety
9. Groundbreaking research could ignite new solutions to heat transfer in nano-devices
10. New hydrothermal vents discovered as South Pacific Odyssey research begins
11. University of Alberta researcher looks for clues to mysterious disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/21/2020)... ... ... Law Enforcement has always been a highly stressful career – serving to protect, ... and women put them constantly in harm’s way both from the criminal element as ... to face very high daily stress. Now, COVID-19 introduces another even greater degree of ...
(Date:5/15/2020)... ... ... The National Institutes of Health (NIH) has selected McBee Moore & Vanik IP, ... Virginia, to provide patent legal services under two separate ten (10) year contracts: one ... firm is one of nine firms in the nation awarded a biotechnology contract and ...
(Date:5/14/2020)... ... May 13, 2020 , ... DuPont Nutrition & Biosciences (DuPont) ... lactose-free dairy market. This unique product allows for process optimization and cost reduction, ... costs across North America. , Among the numerous benefits Bonlacta™ offers, it is ...
Breaking Biology News(10 mins):
(Date:5/15/2020)... ... May 14, 2020 , ... ... (hMSC) working cell banks and hMSC bioprocess systems, today announced the launch ... of hMSC-derived extracellular vesicles (EVs). RoosterCollect™-EV-CC is the only system designed with ...
(Date:5/15/2020)... ... ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches to cell therapy, ... continue to lead Sentien’s Board of Directors, a role he has filled for the ... management team. , Mr. Ganz has more than 30 years of experience ...
(Date:5/14/2020)... SAN FRANCISCO (PRWEB) , ... May 13, 2020 ... ... new content hub called Future Lab: Optimizing Workflows in the Life Science ... them optimize workflows in their lab, from water purification and liquid handling to ...
(Date:5/5/2020)... ... May 04, 2020 , ... ... the life sciences industry, today announced that Informa Training Partners, a life sciences ... name to Red Nucleus Boston, effective immediately. , “The name change solidifies a ...
Breaking Biology Technology:
Cached News: